Climb Bio, Inc. Common Stock

CLYM XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

740M

Short interest (Jul 15)

12.0%

Net Short (Jul 27 ): -0.1%

Borrow Fee

0.41%

↑ 2.4%

Available Shares

500K

↓ 57.4%

Price Chart

Company Overview

Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001768446

Asset Type: CS

Market Data

Market Cap: $735,257,215

Employees: 29

Status: Active

Short Interest

Current Borrow Fee 0.41%

Range: 0.41% - 0.41%

Available Shares 500K

Range: 250K - 500K

Recent Changes

Fee Change: ↑ 0.0%

Available Change: ↓ 30.0%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime